Paxman AB (PAX)

Currency in SEK
55.00
+8.10(+17.27%)
Closed·
Unusual trading volume
PAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
49.0555.90
52 wk Range
41.0080.80
Key Statistics
Prev. Close
55
Open
49.05
Day's Range
49.05-55.9
52 wk Range
41-80.8
Volume
153.3K
Average Vol. (3m)
26.96K
1-Year Change
-26.4706%
Book Value / Share
17.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Paxman AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Paxman AB Earnings Call Summary for Q2/2026

  • Paxman Q2 sales surged 40% YoY to record 105.1M SEK; EBITDA hit 14M SEK with 13% margin; shares jumped 15.35% to $54.1 in premarket trading.
  • U.S. revenue climbed 77.5% to $7.1M driven by insurance-based billing model, which grew 110% quarter-over-quarter with 1,326 caps sold through the program.
  • Company holds 105M SEK cash and 190-system order book; deployed 56 systems in Q2 with 80 units pending installation in U.S. market alone.
  • Management expects continued insurance billing growth but at slower pace; five OneOncology practices signed with Q4 2026 revenue impact anticipated.
  • FDA De Novo application for neuropathy device submitting this month; clearance expected April-August 2027 with U.S. commercialization targeted for Q2 2027.
Last Updated: 08/21/2026, 03:43 AM
Read Full Transcript

Earnings

Latest Release
Aug 21, 2026
EPS / Forecast
-- / 0.50
Revenue / Forecast
105M / 98.85M
EPS Revisions
Last 90 days

PAX Income Statement

Compare PAX to Peers and Sector

Metrics to compare
PAX
Peers
Sector
Relationship
P/E Ratio
−226.8x−3.6x−0.4x
PEG Ratio
-0.000.00
Price / Book
3.1x1.5x2.6x
Price / LTM Sales
3.5x1.5x3.1x
Upside (Analyst Target)
70.0%−12.9%48.6%
Fair Value Upside
Unlock9.2%5.8%Unlock

Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.

Employees
143
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
359.45K1.54%19.77M
Other Institutional Investors
9.09M39.05%499.81M
Public Companies & Retail Investors
13.83M59.41%760.46M
Total
23.27M100.00%1.28B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Avanza Fonder AB5.47%1,271,91269,955
Lansforsakringar Fondforvaltning AB4.82%1,121,61661,689

People Also Watch

35.00
W5
-0.43%
3.100
CDGI
-0.64%
24.50
XPLRA
+4.26%

FAQ

What Is the Paxman (PAX) Stock Price Today?

The Paxman stock price today is 55.00 SEK.

What Stock Exchange Does Paxman Trade On?

Paxman is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Paxman?

The stock symbol for Paxman is "PAX."

What Is the Paxman Market Cap?

As of today, Paxman market cap is 1.28B SEK.

When Is the Next Paxman Earnings Date?

Paxman will release its next earnings report on Nov 20, 2026.

From a Technical Analysis Perspective, Is PAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Paxman Stock Split?

Paxman has split 0 times.

How Many Employees Does Paxman Have?

Paxman has 143 employees.

What is the current trading status of Paxman (PAX)?

As of Aug 24, 2026, Paxman (PAX) is trading at a price of 55.00 SEK, with a previous close of 55.00 SEK. The stock has fluctuated within a day range of 49.05 SEK to 55.90 SEK, while its 52-week range spans from 41.00 SEK to 80.80 SEK.

What Is Paxman (PAX) Price Target According to Analysts?

The average 12-month price target for Paxman is 93.50 SEK, with a high estimate of 103 SEK and a low estimate of 84 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +70.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.